Abstract:Abstract Background Biological agents represented by Infliximab have brought a milestone leap forward in the treatment of IBD. However, the overall response rate of anti-TNF-α antibodies in clinical practice is just 40-60% and the adverse reactions caused by the lack of gut-selective further limit its clinical application. Systemic effects of intravenous administration may be an essential cause of paradoxical response and immune adaptive succession (secondary loss of response). Rapid advances in synthetic biology allow targeted delivery of antibody drugs via engineered probiotics to improve bioavailability while reducing the risk of systemic effects. Methods Here, we developed an engineered probiotic (EcN-VHH2M3) that intelligently responds to the inflammatory marker thiosulfate and produces the anti-TNF-α nanobody VHH2M3. At the same time, controlled release of anti-TNF-α biologic was achieved in response to colitis marker nitrate and quorum sensing mechanism. The dextran sulfate sodium (DSS)-induced colitis model was used to explore the feasibility of EcN-VHH2M3 for the IBD treatment. The disease activity index of the subject animals was detected and evaluated. The colon length and spleen weight were measured and HE staining. Real-time polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) are used to detect cytokine expression levels in colon tissue. Results In vivo results showed that EcN-VHH2M3 group significantly reduced disease activity index and restored intestinal mucosal barrier compared with control group. DSS administration resulted in hyperemia, ulceration, and thickening of the bowel wall, which were reduced in the treatment group. In addition, spleen weight and colon length were close to the control group. EcN-VHH2M3 treatments significantly decreased the expression levels of pro-inflammatory cytokines IL-1β, TNF-α, and IFN-γ, while the expression of anti-inflammatory cytokines IL-10 and TGF-β was enhanced. Conclusion Inflammatory microenvironment-responsive programmable probiotics effectively alleviate DSS-induced colitis in mice and restore the intestinal mucosal barrier through the targeted release of anti-TNF-α nanobody. This study preliminarily confirmed that the controlled intestinal release of anti-TNF biologics by engineered probiotics provides a promising paradigm for IBD treatment with non-gut-selective antibodies.

An engineered probiotic secreting Sj16 ameliorates colitis via Ruminococcaceae/butyrate/retinoic acid axis

<i>Lactobacillus johnsonii</i> alleviates colitis by TLR1/2-STAT3 mediated CD206<SUP>+</SUP> macrophages<SUP>IL-10</SUP> activation

<i>Lactobacillus johnsonii</i> alleviates colitis by TLR1/2-STAT3 mediated CD206 <sup>+</sup> macrophages <sup>IL-10</sup> activation

Gut microbiota modulation and anti-inflammatory properties of mixed lactobacilli in dextran sodium sulfate-induced colitis in mice

Differential reinforcement of intestinal barrier function by various Lactobacillus reuteri strains in mice with DSS-induced acute colitis

Lactobacillus plantarum strains attenuated DSS-induced colitis in mice by modulating the gut microbiota and immune response

Engineered probiotics with sustained release of interleukin-2 for the treatment of inflammatory bowel disease after oral delivery

Potential of using an engineered indole lactic acid producing Escherichia coli Nissle 1917 in a murine model of colitis

Propionate‐producing engineered probiotics ameliorated murine ulcerative colitis by restoring anti‐inflammatory macrophage via the <scp>GPR43</scp>/<scp>HDAC1</scp>/<scp>IL</scp>‐10 axis

Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery

Propionate‐producing engineered probiotics ameliorated murine ulcerative colitis by restoring anti‐inflammatory macrophage via the GPR43/HDAC1/IL‐10 axis

OP26 Programmable probiotic local delivery of anti-TNF-α nanobody to alleviate DSS-induced colitis

The Administration of Escherichia coli Nissle 1917 Ameliorates Development of DSS-Induced Colitis in Mice

Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis

Modified Prebiotic-Based "Shield" Armed Probiotics with Enhanced Resistance of Gastrointestinal Stresses and Prolonged Intestinal Retention for Synergistic Alleviation of Colitis

Bifidobacterium bifidum Ameliorates DSS-Induced Colitis in Mice by Regulating Microbial Metabolome and Targeting Gut Microbiota

rSj16 Protects against DSS-Induced Colitis by Inhibiting the PPAR-α Signaling Pathway.

Bacteroides acidifaciens and its derived extracellular vesicles improve DSS-induced colitis

A tailored series of engineered yeasts for the cell-dependent treatment of inflammatory bowel disease by rational butyrate supplementation

IDDF2024-ABS-0288 Engineered Probiotic with High Tryptophan Synthesis Capability Protects Against Inflammatory Bowel Disease

Oral administration of RDP58 ameliorated DSS-induced colitis in intestinal microbiota dependent manner